Results 41 to 50 of about 59,490 (287)
Virus-like particles as vaccine.
Acta Biochimica Polonica, 2014 This review presents data on commercial and experimental virus-like particle (VLP) vaccines, including description of VLP vaccines against influenza. Virus-like particles are multimeric, sometimes multiprotein nanostructures assembled from viral structural proteins and are devoid of any genetic material. VLPs present repetitive high-density displays of
Jadwiga, Chroboczek +2 more
openaire +3 more sources
Cross-Protection Induced by Virus-like Particles Derived from the Influenza B Virus
Biomedicines, 2022 The mismatch between the circulating influenza B virus (IBV) and the vaccine strain contributes to the rapid emergence of IBV infection cases throughout the globe, which necessitates the development of effective vaccines conferring broad protection. Here,
Hae-Ji Kang +5 more
doaj +1 more source
Influenza virus-like particle vaccines
Expert Review of Vaccines, 2009 Enveloped virus-like particle (VLP) vaccines containing influenza hemagglutinin (HA) and neuraminidase (NA) antigens are produced easily in insect or mammalian cells via the simultaneous expression of HA and NA along with a viral core protein, such as influenza matrix (M1) or a retroviral Gag protein.
openaire +2 more sources
Virus-like particle vaccines: immunology and formulation for clinical translation
Expert Review of Vaccines, 2018 Introduction: Virus-like particle (VLP) vaccines face significant challenges in their translation from laboratory models, to routine clinical administration. While some VLP vaccines thrive and are readily adopted into the vaccination schedule, others are
Braeden Donaldson +4 more
doaj +1 more source
Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges. [PDF]
, 2019 Introduction: Tuberculosis (TB) remains a major health threat and it is now clear that the current vaccine, BCG, is unable to arrest the global TB epidemic. A new vaccine is needed to either replace or boost BCG so that a better level of protection could
Barclay WR +8 more
core +1 more source
Virus-like particles as vaccine adjuvants
Molecular Biotechnology, 2001 Virus-like particles (VLPs) consist of one or more viral coat proteins that assemble into particles. They can be taken up by antigen presenting cells (APC), peptides derived from them are presented on MHC class I molecules at the cell surface, and thereby prime a CD8+ T cell response, either against the particle-forming protein itself (such as ...
openaire +3 more sources
Zika virus-like particle (VLP) based vaccine
PLOS Neglected Tropical Diseases, 2017 The newly emerged mosquito-borne Zika virus poses a major public challenge due to its ability to cause significant birth defects and neurological disorders. The impact of sexual transmission is unclear but raises further concerns about virus dissemination.
Hélène Boigard +5 more
openaire +4 more sources
The peptide motif of the single dominantly expressed class I molecule of the chicken MHC can explain the response to a molecular defined vaccine of infectious bursal disease virus (IBDV) [PDF]
, 2013 In contrast to typical mammals, the chicken MHC (the BF-BL region of the B locus) has strong genetic associations with resistance and susceptibility to infectious pathogens as well as responses to vaccines.
Butter, Colin +4 more
core +1 more source
Virus-Like-Vaccines against HIV
Vaccines, 2018 Protection against chronic infections has necessitated the development of ever-more potent vaccination tools. HIV seems to be the most challenging foe, with a remarkable, poorly immunogenic and fragile surface glycoprotein and the ability to overpower ...
Anne-Marie C. Andersson +2 more
doaj +1 more source
The potential for reassortment between Oropouche and Schmallenberg Orthobunyaviruses [PDF]
, 2017 A number of viruses within the Peribunyaviridae family are naturally occurring reassortants, a common phenomenon for segmented viruses. Using a minigenome-reporter and virus-like particle (VLP) production assay, we have accessed the potential of ...
Elliott, Richard M. +3 more
core +1 more source